145 related articles for article (PubMed ID: 38039999)
1. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer.
Mutlu Sütcüoğlu B; Sütcüoğlu O
Lancet Oncol; 2023 Dec; 24(12):e457. PubMed ID: 38039999
[No Abstract] [Full Text] [Related]
2. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer - Authors' reply.
Aronson SL; Sonke GS; van Driel WJ
Lancet Oncol; 2023 Dec; 24(12):e458. PubMed ID: 38040000
[No Abstract] [Full Text] [Related]
3. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Kim SI; Kim JW
ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
[TBL] [Abstract][Full Text] [Related]
4. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
Schwameis R; Chiva L; Harter P
Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
[No Abstract] [Full Text] [Related]
5. Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
Wethington SL; Armstrong DK; Johnston FM
JAMA Surg; 2022 May; 157(5):383. PubMed ID: 35262650
[No Abstract] [Full Text] [Related]
6. Hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: current evidence-based indications.
Pareja R
Int J Gynecol Cancer; 2023 May; 33(5):841-842. PubMed ID: 36963802
[No Abstract] [Full Text] [Related]
7. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
8. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
Noiret B; Bakrin N; Eveno C
Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
[No Abstract] [Full Text] [Related]
9. Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.
Petrillo M; Anchora LP; Scambia G; Fagotti A
Oncologist; 2016 May; 21(5):532-4. PubMed ID: 27009941
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
[TBL] [Abstract][Full Text] [Related]
11. Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer.
Gajarawala S; Pelkowski J; Dorian R; Stanton A; Dinh T
JAAPA; 2021 Aug; 34(8):50-53. PubMed ID: 34320542
[TBL] [Abstract][Full Text] [Related]
12. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
[TBL] [Abstract][Full Text] [Related]
13. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
14. [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer].
Schmalfeldt B
Chirurgie (Heidelb); 2022 Dec; 93(12):1144-1151. PubMed ID: 36201013
[TBL] [Abstract][Full Text] [Related]
15. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
Cascales Campos PA; González Gil A
Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
[No Abstract] [Full Text] [Related]
16. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
Xia Y; Wang H; Zhang J; Wang Y
Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
[TBL] [Abstract][Full Text] [Related]
18. Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer?
Alter R; Turaga K; Lengyel E
JAMA Netw Open; 2020 Aug; 3(8):e2014184. PubMed ID: 32840618
[No Abstract] [Full Text] [Related]
19. Letter to the Editor: Comment on ''Cytoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial''.
Carneiro VCG; Ramalho NM
Ann Surg Oncol; 2022 May; 29(5):3351-3352. PubMed ID: 35166953
[No Abstract] [Full Text] [Related]
20. [Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal cancer?].
Anthuber M; Straßmüller A
Chirurg; 2021 Jun; 92(6):573. PubMed ID: 33885913
[No Abstract] [Full Text] [Related]
[Next] [New Search]
